Should I buy or sell Assembly Biosciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ASMB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares. View ASMB analyst ratings or view top-rated stocks .

What is Assembly Biosciences' stock price target for 2024?

1 analysts have issued 1-year price objectives for Assembly Biosciences' shares. Their ASMB share price targets range from $1.50 to $1.50. On average, they predict the company's stock price to reach $1.50 in the next year. This suggests a possible upside of 48.5% from the stock's current price. View analysts price targets for ASMB or view top-rated stocks among Wall Street analysts .

How have ASMB shares performed in 2024?

Assembly Biosciences' stock was trading at $0.8201 at the beginning of 2024. Since then, ASMB shares have increased by 23.2% and is now trading at $1.01. View the best growth stocks for 2024 here .

When is Assembly Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our ASMB earnings forecast .

How were Assembly Biosciences' earnings last quarter?

Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.16. The biopharmaceutical company earned $6.25 million during the quarter.

When did Assembly Biosciences' stock split?

Shares of Assembly Biosciences reverse split on Monday, February 12th 2024. The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is John McHutchison's approval rating as Assembly Biosciences' CEO?

8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com . John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend.

What other stocks do shareholders of Assembly Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI) , Exelixis (EXEL) , TG Therapeutics (TGTX) , Arbutus Biopharma (ABUS) , AVEO Pharmaceuticals (AVEO) , Sorrento Therapeutics (SRNE) , AbbVie (ABBV) , BioCryst Pharmaceuticals (BCRX) , Gilead Sciences (GILD) and Blueprint Medicines (BPMC) .

Who are Assembly Biosciences' major shareholders?

Assembly Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (0.46%), Acuitas Investments LLC (0.40%), Marquette Asset Management LLC (0.08%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alexander Schornstein, Jason A Okazaki, Jeanette M Bjorkquist, John G Mchutchison , Luisa M Stamm, Michael P Samar, Nicole S White, Timothy A Springer , William E Iv Delaney and William E Iv Delaney . View institutional ownership trends .

How do I buy shares of Assembly Biosciences?

Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ASMB

Assembly Biosciences (ASMB) Stock Price, News & Analysis

$1.01

+0.03 (+3.58%)

(As of 02/9/2024 08:55 PM ET)

Compare

Today's Range: $0.98
▼
$1.05
50-Day Range: $0.73
▼
$1.04
52-Week Range: $0.64
▼
$1.67

Volume: 748,900 shs
Average Volume: 473,929 shs
Market Capitalization: $66.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.50

Get Assembly Biosciences alerts:

Assembly Biosciences MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 48.5% Upside
$1.50 Price Target
Short Interest: Healthy
0.69% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.71
Upright™ Environmental Score
News Sentiment: 0.02
Based on 50 Articles This Week
Insider Trading: Acquiring Shares
$233,995 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.19) to ($1.23) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.07 out of 5 stars

Medical Sector

190th out of 922 stocks

Pharmaceutical Preparations Industry

79th out of 428 stocks

3.0

Analyst's Opinion

Consensus Rating
Assembly Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.50, Assembly Biosciences has a forecasted upside of 48.5% from its current price of $1.01.
Amount of Analyst Coverage
Assembly Biosciences has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.69% of the outstanding shares of Assembly Biosciences have been sold short.
Short Interest Ratio / Days to Cover
Assembly Biosciences has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Assembly Biosciences has recently increased by 125.67%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Assembly Biosciences does not currently pay a dividend.
Dividend Growth
Assembly Biosciences does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Assembly Biosciences has received a 74.27% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for infectious diseases", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Assembly Biosciences is -0.71.

2.8

News and Social Media Coverage

News Sentiment
Assembly Biosciences has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 50 news articles for Assembly Biosciences this week, compared to 24 articles on an average week.
Search Interest
8 people have searched for ASMB on MarketBeat in the last 30 days.
MarketBeat Follows
7 people have added Assembly Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Assembly Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $233,995.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.10% of the stock of Assembly Biosciences is held by insiders.
Percentage Held by Institutions
Only 19.92% of the stock of Assembly Biosciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Assembly Biosciences are expected to decrease in the coming year, from ($1.19) to ($1.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Assembly Biosciences is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Assembly Biosciences is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Assembly Biosciences has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Assembly Biosciences Stock (NASDAQ:ASMB)

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

ASMB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ASMB Stock News Headlines

February 12, 2024 | msn.com

6 BJP MLAs including LoP Suvendu Adhikari suspended over "unruly and disorderly behaviour" for remainder of WB Assembly session

February 11, 2024 | msn.com

No phone jammers now, 5G to get more MLAs into Karnataka Assembly

February 12, 2024 | The Freeport Society (Ad)

Obama’s 2024 Confession

Barack Obama’s confession about the 2024 election just leaked online… In short, he’s worried Biden “could very well lose.” But before you think that means Trump will win… You should see the evidence I’ve found about an election shock that could come as soon as August 19th.

February 11, 2024 | msn.com

3 Republicans, 3 Democrats Vie for Open Seat in E. County 75th Assembly District

February 11, 2024 | uk.finance.yahoo.com

Assembly Biosciences Inc (V7B1.MU)

February 11, 2024 | msn.com

The meeting of the newly elected National Assembly is likely to be held on February 29

February 11, 2024 | msn.com

SLO County State Assembly member Dawn Addis is out on medical leave. Here's what happened

February 10, 2024 | news.yahoo.com

SLO County State Assembly member Dawn Addis is out on medical leave. Here’s what happened

February 12, 2024 | The Freeport Society (Ad)

Obama’s 2024 Confession

February 10, 2024 | msn.com

Andhra Pradesh Assembly polls: Congress announces its first candidate; names Vantala Subbarao

February 10, 2024 | msn.com

Benue Killings: Assembly summons security adviser, heads of state’s security outfits

February 10, 2024 | americanbankingnews.com

Assembly Biosciences Stock to Reverse Split on Monday, February 12th (NASDAQ:ASMB)

February 9, 2024 | msn.com

5 Maryland education issues to watch during the 2024 General Assembly session

February 9, 2024 | msn.com

Emotional Farewell Marks Conclusion of 16th Odisha Assembly Session

February 9, 2024 | msn.com

Creative Assembly begs Total War: Warhammer fans to come back with upgraded DLC that adds a giant terracotta warrior

February 9, 2024 | msn.com

WATCH: Assembly Hall Celebrates Chloe Moore-McNeil's Triple-Double

February 8, 2024 | finanznachrichten.de

Assembly Biosciences, Inc.: Assembly Biosciences Announces Effective Date of Reverse Stock Split

February 8, 2024 | msn.com

New Assembly Commission to be appointed early next week

February 8, 2024 | msn.com

Reichlin-Melnick sticks with state Senate run after toying with campaign for Assembly

February 8, 2024 | msn.com

Assembly Brewing, a pioneer of Detroit-style pizza in Portland, to open Alberta Street location

February 8, 2024 | finance.yahoo.com

Assembly Biosciences Announces Effective Date of Reverse Stock Split

February 8, 2024 | msn.com

California Assembly District 8 race has four candidates. What are their priorities?

February 8, 2024 | msn.com

Uttarakhand Assembly Passes Uniform Civil Code Bill: Key Highlights And Implications

February 7, 2024 | news.yahoo.com

Marylanders weigh in on Gov. Moore’s State of the State address to General Assembly

February 7, 2024 | msn.com

Osun Assembly suspends LG chairman for misconduct

February 7, 2024 | msn.com

"Historic day in history of Uttarakhand": Chief Minister Dhami after Assembly's nod to UCC bill

February 7, 2024 | msn.com

Assembly District 8 race wide open with four candidates. What are their priorities?

See More Headlines

Receive ASMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Assembly Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 2/11/2024
Next Earnings (Estimated): 3/27/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:ASMB
CUSIP: 92282210
CIK: 1426800
Web: www.assemblybio.com
Phone: (833) 509-4583
Fax: 646-706-5101
Employees: 68
Year Founded: 2005

Price Target and Rating

Average Stock Price Target: $1.50
High Stock Price Target: $1.50
Low Stock Price Target: $1.50
Potential Upside/Downside: +48.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.42)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-93,090,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -116.42%
Return on Assets: -95.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.96
Quick Ratio: 6.96

Sales & Book Value

Annual Sales: $6.25 million
Price / Sales: 10.63
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.69 per share
Price / Book: 0.60

Miscellaneous

Outstanding Shares: 65,790,000
Free Float: 63,095,000
Market Cap: $66.45 million
Optionable: Optionable
Beta: 0.52

Social Links

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. Jason A. Okazaki (Age 48)
CEO, President & Director
Comp: $869.28k
Dr. William E. Delaney IV (Age 52)
Ph.D., Chief Scientific Officer
Comp: $664.4k
Dr. Uri A. Lopatin M.D. (Age 52)
Co-Founder and Clinical & Scientific Advisor
Comp: $608.55k
Dr. Adam Zlotnick
Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board
Jeanette M Bjorkquist
Executive Director of Accounting & Treasury
Shannon Ryan
Senior Vice President of Investor Relations, Corporate Affairs & Alliance Management
Ms. Jennifer A. Troia MHROD
SHRM-SCP, SPHR, Chief Human Resources Officer
Dr. Nicole S. White Ph.D.
Chief Manufacturing Officer
Dr. Anuj Gaggar M.D.
Ph.D., Chief Medical Officer
Mr. Thomas E. Rollins (Age 68)
Executive Officer
Comp: $472.55k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ASMB Stock Analysis - Frequently Asked Questions

Should I buy or sell Assembly Biosciences stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ASMB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ASMB, but not buy additional shares or sell existing shares.
View ASMB analyst ratings or view top-rated stocks.
What is Assembly Biosciences' stock price target for 2024?: 1 analysts have issued 1-year price objectives for Assembly Biosciences' shares. Their ASMB share price targets range from $1.50 to $1.50. On average, they predict the company's stock price to reach $1.50 in the next year. This suggests a possible upside of 48.5% from the stock's current price.
View analysts price targets for ASMB or view top-rated stocks among Wall Street analysts.
How have ASMB shares performed in 2024?: Assembly Biosciences' stock was trading at $0.8201 at the beginning of 2024. Since then, ASMB shares have increased by 23.2% and is now trading at $1.01.
View the best growth stocks for 2024 here.
When is Assembly Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our ASMB earnings forecast.
How were Assembly Biosciences' earnings last quarter?: Assembly Biosciences, Inc. (NASDAQ:ASMB) issued its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.57) by $0.16. The biopharmaceutical company earned $6.25 million during the quarter.
When did Assembly Biosciences' stock split?: Shares of Assembly Biosciences reverse split on Monday, February 12th 2024. The 1-12 reverse split was announced on Monday, February 12th 2024. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, February 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is John McHutchison's approval rating as Assembly Biosciences' CEO?: 8 employees have rated Assembly Biosciences Chief Executive Officer John McHutchison on Glassdoor.com. John McHutchison has an approval rating of 80% among the company's employees. 76.0% of employees surveyed would recommend working at Assembly Biosciences to a friend.
What other stocks do shareholders of Assembly Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Assembly Biosciences investors own include BioDelivery Sciences International (BDSI), Exelixis (EXEL), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), AVEO Pharmaceuticals (AVEO), Sorrento Therapeutics (SRNE), AbbVie (ABBV), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and Blueprint Medicines (BPMC).
Who are Assembly Biosciences' major shareholders?: Assembly Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (0.46%), Acuitas Investments LLC (0.40%), Marquette Asset Management LLC (0.08%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alexander Schornstein, Jason A Okazaki, Jeanette M Bjorkquist, John G Mchutchison, Luisa M Stamm, Michael P Samar, Nicole S White, Timothy A Springer, William E Iv Delaney and William E Iv Delaney.
View institutional ownership trends.
How do I buy shares of Assembly Biosciences?: Shares of ASMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ASMB) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Assembly Biosciences (ASMB) Stock Price, News & Analysis

Assembly Biosciences MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Assembly Biosciences Stock (NASDAQ:ASMB)

ASMB Stock Price History

ASMB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ASMB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™